New HIV Prevention Drug Holds Promise for Australia

New HIV Prevention Drug Holds Promise for Australia

A twice-yearly injection could help Australia eliminate HIV, but experts are sounding the alarm over its prohibitive cost.

FDA to Evaluate Merck’s Doravirine, Islatravir Regimen for HIV-1

The FDA set a Prescription Drug User Fee Act (PDUFA) date of April 28, 2026.

FDA Accepts New Drug Application for Merck’s HIV Treatment, Doravirine/Islatravir

This investigational two-drug regimen for treatment of adults with virologically suppressed HIV was given a Prescription Drug User Fee Act (PDUFA) date of April 28, 2026.